Jasper Therapeutics GAAP EPS of -$0.32 beats by $0.48 [Seeking Alpha]
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab [Yahoo! Finance]
Jasper Therapeutics (JSPR) is now covered by UBS Group AG. They set a "neutral" rating and a $1.50 price target on the stock.
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference [Yahoo! Finance]